VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

pCgap DNA vaccine encoding glyceraldehyde-3-phosphate dehydrogenase
Vaccine Information
  • Vaccine Name: pCgap DNA vaccine encoding glyceraldehyde-3-phosphate dehydrogenase
  • Target Pathogen: Haemophilus parasuis
  • Target Disease: Glasser's disease
  • Vaccine Ontology ID: VO_0004515
  • Type: DNA vaccine
  • Status: Research
  • gapA gene engineering:
    • Type: DNA vaccine construction
    • Description:
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid: pcDNA3.1/V5-His-TOPO DNA vaccine plasmid
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Vaccination Protocol: Four to five week old female BALB/c mice were divided randomly into three groups (30 mice per group): one group was injected intramuscularly in the hind thigh muscle with 100 μg of plasmid dissolved in 100 μl PBS; the other two groups were injected with pcDNA 3.1 vector only as negative control or PBS as blank control. Mice received a vaccination boost of an equivalent dose on day 14 and 28 following the first immunization (Fu et al., 2012).
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: Although IgG analysis showed production of both IgG1 and IgG2, the higher levels of IgG1 indicated the dominance of Th2 response over Th1 response (Fu et al., 2012).
  • Challenge Protocol: Two weeks after the second vaccination boost, mice immunized with pCgap were divided into groups 1 and 2 (12 mice/group). The mice from group 1 were challenged intraperitoneally with a lethal dose of 3.0 × 109 CFU of H. parasuis SH0165 strain and the mice from group 2 were challenged intraperitoneally with a lethal dose of 3.0 × 109 CFU of H. parasuis MD0322 strain. Mice were monitored for seven days post-challenge, and morbidity and mortality were recorded (Fu et al., 2012).
  • Efficacy: The groups vaccinated with the pCgap vaccine exhibited 83.3% and 50% protective efficacy against the H. parasuis MD0322 serovar 4 or SH0165 serovar 5 challenges, respectively (Fu et al., 2012).
References
Fu et al., 2012: Fu S, Zhang M, Ou J, Liu H, Tan C, Liu J, Chen H, Bei W. Construction and immune effect of Haemophilus parasuis DNA vaccine encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in mice. Vaccine. 2012; 30(48); 6839-6844. [PubMed: 23000128].